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The fibrinolytic efficacy and systemic effects on coagu-
lation variables of intracoronary administration of an
aeylated streptokinase-plasminogencomplex(BRL 26921)
were assessed in 23 patients with an acute transmural
myocardial infarction. The infarct vessel was totally oc-
cluded in 22 patients and subtotally stenosed in 1 patient.
Reperfusion was achieved in a total of 17patients (74%),
in 2 patients with the use of a guide wire. Reperfusion
time in those patients treated with BRL 26921 alone
amounted to 42 ± 37 minutes. Reocclusion occurred in
two patients subsequently. Four patients died; in two of
these, intracoronary thrombolysis was unsuccessful.
Reptilase time increased from 13 ± 3 to 49 ± 31
seconds (p < 0.001), fibrinogen levels decreased from
----------------------
Fibrinolytic therapy, instituted early after acute myocardial
infarction either by intracoronary (1-4) or intravenous (5,6)
reperfusion, seems to have beneficial effects on many pa-
tients. Nevertheless, this therapy is not without risk and
severe bleeding complications occur mainly because of pe-
ripheral hyperplasminemia with degradation of peripheral
coagulation factors such as fibrinogen and factors V and
VIII (7 I. Such complications have been described in patients
treated with intracoronaryor intravenous streptokinase(8-10) .
Selective fibrinolysis without major effects on peripheral
coagulation factors remains an ideal therapeutic goal. A
novel thrombolytic agent has been developed, which is a
streptokinase-plasminogen complex acylated at its catalytic
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280 ± 6S to 126 ± 76 mg% (p < 0.001). Factor V
decreased from 96 ± 11 to S3 ± 26% (p < 0.001), and
factor VIII from 99 ± 1 to SS ± 36% (p < 0.001).
Peripheral hyperplasminemia, defined as a reduction of
fibrinogen « 100 mg%) with a reduction of factor V
and VIII « 7S%) simultaneously occurred in eight pa-
tients. Six (75%) of these 8 patients demonstrated re-
perfusion, whereas 9 (64%) of 14 patients without pe-
ripheral hyperplasminemia were also successfully
reperfused. Bleeding complications occurred in two pa-
tients who demonstrated hyperplasminemia. Thus, ef-
fective intracoronary thrombolysiscould be achievedwith
only minor effects on peripheral coagulation variables
in the majority of patients.
center (11). In animal experiments (11,12), clot lysis has
been achieved with that agent with or without only minimal
systemic fibrinolytic effects. The present study evaluated
for the first time the fibrinolytic efficacy of this compound
and the effects on coagulation variables in patients with
acute myocardial infarction and a thrombotic occluded coro-
nary vessel .
Methods
Patients. Twenty-three consecutive patients with clini-
cal symptoms and electrocardiographic findings consistent
with acute transmural myocardial infarction were studied .
There were 17 men and 6 women with a mean age of 58
± 9 years. The duration of clinical symptoms on admission
to hospital was 137 ± 87 minutes. Patients were instructed
about the study protocol and gave informed consent in the
presence of a witness. Patients were required to have no
contraindication to thrombolytic therapy .
Study protocol. Before coronary angiography, patients
were treated with 1.6 mg nitroglycerin and 20 mg nifedipine
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sublingually; thereafter, a continuous intravenous infusion
of nitroglycerin at I to 3 mg/h was started. Left heart cath-
eterization was performed using the femoral approach.
Coronary angiography was done with the Judkins technique.
After coronary catheter insertion into the infarct vessel, 0.4
mg nitroglycerin was administered. Since an effective dose
range for the acylated streptokinase-plasminogen complex
has not yet been substantiated in human subjects, I patient
received 5 mg aRL 26921, 13patients received 10 mg and
9 patients received 20 mg by intracoronary infusion at a rate
of 0.5 mg/min. Repeat coronary angiography every 10 min-
utes was performed up to 90 minutes after infusion to assess
fibrinolytic efficacy of the compound. Heparin therapy was
instituted 6 hours after the end of the BRL 26921 infusion,
with doses ranging from 1,000 to 1,200 Ulh. Control coro-
nary angiograms were obtained 24 to 48 hours later to assess
patency of the infarct vessel.
Coagulation variables. Coagulation studies were ob-
tained immediately before and after coronary thrombolysis
and every 2 hours up to 24 hours and at intervals of 4 to
36 hours. Coagulation studies included measurement of rep-
tilase time, fibrinogen, factor V, factor VIII, antithrombin
III, fibrin degradation products and plasminogen. The pres-
ence of hyperplasminemia was defined as a major reduction
of fibrinogen « 100 mg%), factor V « 75%) and factor
VIII « 75%) simultaneously. Specimens were collected
into vacutainer tubes containing 0.5 ml sodium citrate (0.11
nmollliter). After centrifugation at 3,000 revolutions/min
for 5 minutes, the supernatant fluid was stored for 2 hours
at 4°C.
The following assays were used to determine the coag-
ulation variables: reptilase time: test kit, Boehringer
Mannheim FRG, lot no. 126560; fibrinogen: test kit, Boeh-
ringer Mannheim FRG, lot no. 126691; factor V: deficient
plasma test kit, Behring FRG, lot no. ORS 1II2113; factor
VIII: deficient plasma test kit, Imuno-Diagnostica Wien-
Austria; fibrinogen degradation products: thrombo-wellco-
test, Welleorne Reagents; and plasminogen: ACA-Du Pont de
Nemours International, analytic test pack, lot no. D 2735 D.
Drug profile. The acylated complex has a two chain
peptide structure in contrast to free (unacylated) streptoki-
nase-plasminogen complex, which has a three chain peptide
structure. The compound has a molecular weight of 13,100
daltons and is stable when dry. The acylation process renders
the enzyme inert and stabilizes it against protease inhibitors.
Without this acylation, enzymatic inhibition and physiologic
clearance would occur rapidly. The binding properties of
the complex are unchanged. The enzyme has no fibrinolytic
activity before deacylation. When in contact with water or
blood, the complex deacylates by simple hydrolysis. The
deacylation obeys first order kinetics, with a deacylation
constant rate of 2.86 ± 1.46 . 10-4 seconds - I, corre-
sponding to a half-life for deacylation of about 40 minutes
(11). Because no data on the fibrinolytic activity in patients
were present as the study was begun, we started to treat our
patients with an arbitrary dose of 20 mg. Later during the
study, smaller doses were also used.
Statistical analysis. Student's t test for paired data was
used to compare data within groups. A probability value of
less than 0.05 was regarded as significant. All values are
reported as mean values ± I standard deviation.
Results
Clinical course (Table 1). Seven patients had an an-
terior myocardial infarction, 16 patients had a posterior in-
farction. Two of the 23 patients suffered from a reinfarction.
In 22 patients, the involved coronary vessel was totally
occluded. In one patient with anterior myocardial infarction
(Case 20), the vessel was subtotally stenosed. In seven
patients, mechanical reperfusion was tried by the use of
guide wires (Cases 6, 9, 10, II, 16, 17 and 23). This was
successful in two patients (Cases 6 and 16). Reperfusion
time amounted to 29 ± 23 minutes in 15 patients. In two
patients (Cases II and 17), late reperfusion was suggested
according to a decline of the elevated ST segments within
a few minutes and a rapid rise of the serum creatinine kinase
(CK) levels that peaked at II and 14 hours, respectively,
after the start of symptoms. At the time of control coronary
angiography 24 hours later, the infarct vessel was found to
be open. If these two patients were included, total reper-
fusion time was 42 ± 37 minutes. Time from clinical symp-
toms to reperfusion amounted to 257 ± 88 minutes.
Control coronary angiograms 24 to 48 hours later showed
reocclusion in two patients (Cases 2 and 6). A total of four
patients died, one from refractory ventricular tachycardia
and ventricular fibrillation during the cardiac catheterization
procedure (Case 19), one from refractory mechanical asys-
tole 7 hours after catheterization (Case 4), and two from
congestive heart failure (Cases 9 and 21). Intracoronary
thrombolysis was unsuccessful in two of these four patients.
At the beginning of the study, serum CK levels amounted
to 101 ± 90 U/liter. Subsequently, CK levels showed only
small differences between those patients demonstrating re-
perfusion and those with permanent occlusion (1,30 I ±
1,174 U/Jiter reperfusion versus 1,035 ± 1,454 U/liter no
reperfusion). Time to peak CK levels was shorter in the
reperfusion group compared with that in the nonreperfusion
group (14.3 ± 5.5 versus 22 ± 9.8 hours, respectively).
Coagulation variables (Table 2). These were assessed
in 22 patients after the compound had been administered.
Reptilase time increased from 13 :t 3 to 49 :t 31 seconds,
with a mean maximal increase after 168 ± 159 minutes
(Fig. I). Factor V decreased from 96 ± II to 53 ± 26%,
with a decrease of more than 75% in 18 patients. Factor V
was normalized in most patients after 10 hours (Fig. 2).
Factor VIII levels decreased from 99 :t I to 55 ± 36%
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Table 1. Clinical Profile of 23 Patients
Time From CK CK
Age (yr) Lysis to Reperfusion AP Dose Peripheral Before Lysis Max
Case &Sex Vessel Reperfusion (min) (mg) Hyperplasminemia (U/liter) (Ulliter)
1 62M LAD + 90 20 136 5,310
2 57M RCA + 18 20 + 65 1,581
3 43M LAD + 10 20 + 65 1,734
4 64M Cx 20 380 992
5 54M RCA + 35 10 47 1,500
6 44M RCA + 26 20 57 2,427
7 50M RCA + 40 10 + 25 847
8 52M RCA + 20 20 44 695
9 71F LAD 10 51 1,237
10 70F RCA 20 47 962
11 57M RCA + 120 10 133 1,233
12 51M RCA + 18 10 25 157
13 51M RCA 10 127 865
14 72F RCA + 17 10 56 944
15 69M RCA + 48 10 87 1,091
16 46M RCA + 22 10 + 29 557
17 64M LAD + 120 20 + 27 862
18 56F RCA + 22 10 + 78 774
19 63M LAD + 20 20 20
20 74F LAD 0 10 + 253 257
21 69F RCA + 25 5 219 807
22 52M LAD + 21 10 + 146 1,335
23 56M RCA 10 212 1,120
Mean ± SO 58 ± 9 42 ± 37 13.7 ± 5.3 101 ± 90 1,240 ± 1,033
AP = acylated plasminogen activator; CK = creatine kinase; Cx = circumflex coronary artery; F = female; LAD = left anterior descending artery;
M = male; RCA = right coronary artery; + = present; ~ = no rcperfusion; 0 in Case 20 = vessel subtotally stenosed.
and were within normal limits after 6 hours in most patients
(Fig. 3) Fibrinogen levels decreased from 280 ± 65 to 126
± 76 mg%. Only 10 of 23 patients had levels below 100
mg% (Fig. 4). Fibrinogen degradation products were de-
tected in all except three patients after the administration of
BRL 26921. Plasminogen decreased from 112 ± 18 to 42
± 24CJi. Levels of antithrombin III were reduced, but were
within a normal range (21 ± 3 to 19 ± 3 IU/ml, p <
0.001).
Evidence of peripheral hyperplasminemia was observed
in eight patients. The mean dose of BRL 26921 in those
patients demonstrating hyperplasminemia was 0.19 ± 0.07
mg/kg, which was only slightly but not significantly higher
compared with that in patients without peripheral hyper-
plasminemia (0.18 ± 0.06 mg/kg). Six of 8 patients with
peripheral hyperplasminemia demonstrated reperfusion,
whereas reperfusion was achieved in 9 of 14patients without
peripheral hyperplasminemia.
Complications. The drug was well tolerated by the pa-
tients. A slight increase in temperature was commonly seen.
Two patients (Cases 16 and 18) with peripheral hyperplas-
minemia demonstrated local oozing from the puncture side.
Blood transfusion was not necessary.
Discussion
Acylated streptokinase-plasminogen complex.
Activation of plasminogen to plasmin starts the fibrinolytic
cascade. However, systemic activation of plasminogen un-
bound to fibrin is not important for effective thrombolysis
and is mainly responsible for the depletion of fibrinogen,
factors V and VIIl and bleeding complications. It is the
fibrin-bound activation of plasminogen that mediates the
fibrinolytic process and clot lysis (13). Thus, the ratio of
systemic to fibrin-bound plasminogen activation determines
whether the therapeutic ratio between fibrinolytic efficacy
and systemic fibrinolytic effects is high.
An acylated streptokinase-plasminogen complex had been
developed that demonstrated fibrinolytic efficacy with re-
duced systemic effect on coagulation variables in animal
experiments (11,12). If such a concept is applicable in hu-
man subjects, a substance like BRL 26921 can be safely
administered intravenously to achieve clot lysis with only
minor effects on coagulation variables. Initial clinical ex-
periments (14) in healthy volunteers have shown that 5 to
7 mg of BRL 26921 has only minimal effects on coagulation
variables. In this study, a mean dose of 14 mg of BRL
26921 was given to 23 patients with acute myocardial in-
farction. This is equivalent to a dose of 500,000 IU strep-
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Reptilase Time Fibrinogen Factor V Factor VIII FOP Plasminogen -<
'"(seconds) (mg%) (%) (%) ( /Lg/ml) (%) U;
:E
Case Before After Before After Before After Before After Before After Before After ::;:I:
>
1 10 106 280 24 100 42 100 83 0 960 112 20
'"r-2 10 46 243 37 100 51 100 66 0 - 119 29 >
'"3 16 49 310 88 100 68 100 28 0 240 94 28 ~
4 19 11 310 280 100 100 100 100 0 60 107 103 Z
°5 12 19 350 265 79 46 100 100 0 30 114 76 0m
6 II 31 290 112 100 55 100 100 0 120 112 48 z>
7 14 35 225 61 100 40 100 62 0 120 87 26 8
8 12 19 220 200 100 100 100 100 0 0 85 75 -<>9 16 26 250 161 100 58 96 55 0 0 102 45 ....,
°10 12 50 350 110 100 49 100 34 0 240 91 23 ;:0
11 II 48 306 104 100 43 100 10 0 120 102 35
12 9 25 111 215 100 82 100 65 0 0 140 51
13 13 13 327 238 100 70 100 100 0 60 113 82
14 I I 54 360 70 100 100 100 56 0 120 121 16
15 12 39 270 110 100 63 100 65 0 120 119 38
16 17 45 145 85 100 10 100 10 0 480 103 26
17 13 69 270 48 69 17 100 22 0 120 99 20
18 17 120 315 50 62 17 100 17 0 480 158 24
19 14 - 284 - 100 - 100 - 0 - 110
20 17 120 383 80 100 45 100 10 0 240 120 20
21 13 44 234 170 100 41 100 11 0 480 134 57
22 11 66 300 85 100 27 100 10 0 120 121 20
23 15 31 320 170 100 41 100 100 0 60 117 57
Mean ± SO 13.3 ± 2.7 48.5 ± 31.4 280.6±65 125.6 ± 75.5 96.1 ± 10.7 53.0 ± 25.8 99.8 ± 0.8 54.7 ± 35.9 0 198.6 ± 231.3 112.2± 18 41.8 ± 24.3
p < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001
FOP = fibrin degradation products.
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Figure l. Time course ofreptilase time values during BRL 26921
therapy Dotted line represents the upper limit of normal. C ==
control.
Figure 3. Time course of factor VlIl levels during BRL 26921
therapy. The hatched area represents the normal range. C
control.
tokinase (14) . Since this is the first study to evaluate the
effects of this thrombolytic agent in patients, we did not
intend to perform a randomized study of that compound
versus conventional streptokinase therapy. Thus, a direct
comparison could not be made .
Systemic fibrinolytic effects. Systemic fibrinolytic ef-
fects with a reduction of fibrinogen below 100 mg% were
seen in only 43% of the patients . Recently, systemic fi-
brinolytic effects during and after intracoronary streptoki-
nase therapy were found in 88% of 25 infarct patients with
a mean dose of 201,000 ± 74,000 IU of streptokinase (10).
In another study, the same authors (15) found a pronounced
reduction in fibrinogen levels in 8 (73%) of 11 patients with
a mean dose of 131,000 ± 17,000 lU of streptokinase.
Mandelkorn et al. (16) described systemic fibrinolytic ef-
fects in 13 (76%) of 17 patients with doses of streptokinase
ranging from 220,000 to 354,000 IU. Tabari et al. (17)
observed a pronounced reduction in fibrinogen within 12
hours in 17 patients who received a mean dose of strepto-
kinase of 233,000 IU (range 130,000 to 350,0(0). Com-
pared with control values , fibrinogen levels decreased from
282 ± 72 to 45 ± 32 mg% immediately after infusion and
remained still strikingly low after 12 hours at 80 ± 50
mg%. The lowest fibrinogen levels in all these studies were
Figure 2. Time course of factor V levels during BRL 26921
therapy. The hatched area represents the normal range. C =
contra].
Figure 4. Time course of fibrinogen levels during BRL 26921
therapy. The hatched area represents the normal range. C =
control.
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found immediately postinfusion, whereas in our study the
mean maximal decrease occurred after 3 hours.
Some authors stated that only minimal effects on coag-
ulation variables were observed during streptokinase therapy
either by intracoronary (18) or intravenous (5) infusion.
These discrepancies may be due in part to different fibrin-
ogen assay methods used in these studies. Observed bleed-
ing complications, however, were generally associated with
a pronounced decrease in fibrinogen levels (9).
The time course of the fibrinolytic effect on coagulation
variables has not been thoroughly studied. Furthermore, it
is not known whether the duration of the fibrinolytic effect
has any influence on the patency rate of the vessel. Reptilase
time as an index of the fibrinolytic power of therapy was
prolonged for more than 10 hours in our study. The pro-
longed fibrinolytic efficacy of the new compound might be
useful in preventing reocclusion, although two patients dem-
onstrated reocclusion on coronary angiograms repeated within
48 hours.
Reperfusion rate. Reperfusion attributed solely to the
fibrinolytic therapy was achieved in 15 (68%) of 22 patients
in this study, which is in the range reported for conventional
streptokinase therapy. Reperfusion time was 42 ± 37 min-
utes, and, thus, was longer than that described during in-
tracoronary streptokinase therapy (1,2,4,15,18) and com-
parable with that during intravenous administration of
streptokinase (5,6).
Peripheral hyperplasminemia. Depletion of systemic
plasminogen may also be hazardous to the patient because
subsequent thrombi might become resistant to further lysis.
Cowley et al. (10) reported a 93% reduction in plasminogen
levels in patients receiving a mean dose of 21,000 IV of
streptokinase. There was a reduction in plasminogen of more
than 80% for those patients receiving more than 120,000
IV of streptokinase. The mean reduction of plasminogen in
our study was considerably less (62%).
Results from monitoring factors V and VIII levels during
streptokinase therapy in infarct patients have not been re-
ported, although plasmin also degradates these coagulation
factors. Levels of factors V and VIII decreased immediately
after the administration of BRL 26921. However, in most
patients, levels of factors V and VIII had returned to normal
within 10 and 6 hours, respectively. During fibrinolytic
therapy, levels of factors V and VIII were within normal
limits in four and seven patients, respectively. Evidence of
peripheral hyperplasminemia was observed in eight patients
(34%). In two of these patients, minor bleeding compli-
cations were observed. No patient without hyperplasmine-
mia demonstrated any hemorrhagic complications. Six (75%)
of 8 patients with hyperplasminemia and 9 (64%) of 14
patients without hyperplasminemia showed reperfusion. The
mean dose of BRL 26921 given in both groups was not
different. Three patients with reperfusion did not show any
increase in fibrinogen degradation products. Thus, the pres-
ence of hyperplasminemia does not seem to be essential to
achieve reperfusion. This is in contrast to the results of a
preliminary report (19) in which it was demonstrated that
fibrinolysis was successful only when systemic effects were
present.
Clinical implications. The compound was well toler-
ated by the patients. After the fibrinolytic efficacy of BRL
26921 has been established in human subjects, further stud-
ies are warranted to evaluate if the acylated plasminogen
activator enhances fibrinolytic therapy and reduces unde-
sirable systemic effects on coagulation variables. The mode
of activation favors intravenous use of this compound in the
future.
We thank the Beecham-Wiilfing GmbH, 4040 Neuss I, West Germany
for kindly supplying us with BRL 26921, and Maureen Elmslie, MD and
George S. Harris, MD for reviewing the manuscript.
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